Telix Pharmaceuticals (ASX:TLX) reported second-quarter revenue rose 21% to $247 million due to strong sale of precision medicine category, according to a Tuesday filing with the Australian bourse.
The company expects fiscal 2026 revenue and other income to be more than $1 billion, with income tracking in line with the upper end of outlook of $950 million to $970 million.
It increased its fiscal 2026 research and development expenditure outlook to $230 million to $270 million from prior range of $200 million to
$240 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.